Bavarian Nordic plans to present updated overall survival data from an NCI sponsored combination study of its active prostate cancer immunotherapy candidate PROSTVAC and ipilimumab, an immune checkpoint inhibitor, at the Genitourinary Cancers Symposium in Orlando, FL on Feb. 26.
Approximately 20 perecent of men with advanced prostate cancer treated with PROSTVAC and Ipilimumab were alive 80 months after initiating treatment. Thirty patients with metastatic castration-resistant prostate cancer were enrolled in the Phase 1 combination study. Patients were treated with PROSTVAC plus escalating doses of ipilimumab. The observed median overall survival was 31.3 months for all dose cohorts and 37.2 months for patients treated at 10 mg/kg based on updated overall survival data.
The senior author for the presentation is Dr. James L. Gulley, Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health.
Source: Bavarian Nordic